Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2008 Jul;49(1):1-5.
doi: 10.1016/j.jhep.2008.04.006. Epub 2008 Apr 28.

Molecular targeted therapies in hepatocellular carcinoma: from pre-clinical models to clinical trials

Pippa Newell, Augusto Villanueva, Josep M Llovet
Editorial

Molecular targeted therapies in hepatocellular carcinoma: from pre-clinical models to clinical trials

Pippa Newell et al. J Hepatol. 2008 Jul.
No abstract available

PubMed Disclaimer

Figures

Fig. 1.
Fig. 1.
Molecular targets of bevacizumab and rapamycin. Bevacizumab is a monoclonal antibody against VEGF, a ligand implicated in the proangiogenic response in human malignancies. Rapamycin is a small molecule blocking mTOR, an important downstream molecule of the Akt pathway. MTOR has been implicated in protein synthesis, cell growth and transition from G1 to S phase of the cell cycle. It can be activated through various growth factor tyrosine kinase receptors.
See this image and copyright information in PMC

Comment on

References

    1. Farazi PA, DePinho RA. Hepatocellular carcinoma pathogenesis: from genes to environment. Nat Rev Cancer 2006;6:674–687. - PubMed
    1. Dancey JE, Chen HX. Strategies for optimizing combinations of molecularly targeted anticancer agents. Nat Rev Drug Discov 2006;5:649–659. - PubMed
    1. Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Raoul J, Zeuzem S, et al. for the SHARP Investigators. Sorafenib improves survival in advanced hepatocellular carcinoma (HCC): results of a phase III randomized placebo-controlled trial. J Clin Oncol 2007;25: LBA1.
    1. Chiang D, Villanueva A, Peix J, Newell P, Wurmbach E, Donovan D, et al. Integrative genomic classification of hepatitis C virus positive hepatocellular carcinoma. Hepatology 2007;46 (Suppl). Abstract #657.
    1. Villanueva A, Newell P, Chiang DY, Friedman SL, Llovet JM. Genomics and signaling pathways in hepatocellular carcinoma. Semin Liver Dis 2007;27:55–76. - PubMed

MeSH terms

Substances